We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.35 | 0.00 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4.20 | 4.50 | 4.35 | 4.35 | 4.35 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -10.36 | 23.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.35 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/7/2024 | 07:00 | UK RNS | Eden Research plc Appointment of Global Product and Marketing Lead |
| 10/7/2024 | 10:12 | UK RNS | Eden Research plc Director/PDMR Shareholding |
| 05/7/2024 | 07:00 | UK RNS | Eden Research plc Grant of Awards Under Long-Term Incentive Plan |
| 27/6/2024 | 19:29 | ALNC |  EARNINGS AND TRADING: Fenikso in profit; Tate & Lyle completes sale |
| 27/6/2024 | 14:52 | UK RNS | Eden Research plc Result of AGM |
| 27/6/2024 | 09:37 | UK RNS | Eden Research plc AGM Statement |
| 27/6/2024 | 07:00 | UK RNS | Eden Research plc Bioinsecticide Field Trials |
| 24/6/2024 | 15:39 | ALNC | Eden Research flagship biofungicide granted new authorisation in Spain |
| 24/6/2024 | 07:00 | UK RNS | Eden Research plc Biofungicide Label Extension in Spain |
| 17/6/2024 | 07:00 | UK RNS | Eden Research plc Eden Research wins at Small Cap Network Awards |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/7/2024 | 03:59 | Eden Research | 18,116 |
| 08/2/2024 | 07:42 | Eden....Onward and Upwards! | 52 |
| 21/6/2023 | 12:05 | The sterile garden of Eden | 123 |
| 29/3/2022 | 16:04 | Eden Research | 14 |
| 29/3/2022 | 14:36 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 27 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.35p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £23,200,835. Eden Research has a price to earnings ratio (PE ratio) of -10.36. This morning EDEN shares opened at 4.35p |
Posted at 22/7/2024 20:05 by investingisatrickygame What about the Regulatory approvals and their value in isolation pre-sales. What is that worth in the share price today?1) We normally hear about 18-24 months for regulatory approval 2) How many regulatory approvals do we have? 3) How many people hours are invested in creating a regulatory submission? 4) How much, on average, does each regulatory submission cost? 5) How much, on average, does a label extension submission cost? 6) We've been told that it takes 8-10 years and $300 million to produce a new pesticide Eden has said the shares are worth north of the Cavendish target of 20p and they are worth this today. Let's randomly pick 25p. That is £133 million market cap. Eden's latest turnover figures were £3.1 million and we made a loss, so forget applying a P/E ratio. So where is the £133 million value today? Know-how, IP, regulatory approvals, time employed! £133 million is $172 million $172 million is 57% of the value cost of bringing one new pesticide to market. £133 million, arguably, represents 3 products (Mevalone, Cedroz, Ecovelex), all of which are really in their infancy. $300 million is £232 million. That would represent a share price of 44p for one product. We have 3, soon to be 4 and with an insecticide label expansion as per the 2023 Placing RNS, one might argue, 5. Even before you start adding in profits to the accounts and applying a P/E ratio, I would say it is clear to see the value in Eden from know-how, IP, regulatory approvals and time employed. Given the time, know-how and cost to create one product, I'd say the big boys wouldn't baulk at paying a lot of money to buy Eden. |
Posted at 21/7/2024 14:59 by investingisatrickygame If you ask management, they will tell you that the addressable market is a moving feast from year to year. That to me, is understandable.Where are we today? We have two products, Mevalone and Cedroz, both with an increasing regulatory footprint, approvals and label extensions. Corteva usually refer in their videos to Ecovelex being their product. In commercial agreements that may not be so, but it is the way they position it. With no incumbent product in Europe (?) the addressable market will be 100% of what is available, will it not?! With a 15 year regulatory approval, when it comes along, that is an awful lot of revenue and profit for both Corteva and Eden. Add Sunflowers, (perhaps) and other geographies and there is no way Corteva is going to want to have anyone else have direct access to 'their' bird repellent, without them being the licensee or re-seller. I mention this because to me, when assessing shareholder value, I can look to Corteva, 15 years, bird repellent and be secure in my mind that this is worth many, many times today's share price. That alone would be a starting point for anyone, in due course, looking to make an offer for Eden. That alone makes Eden a profitable company and a potential bid target. I assume the insecticide will be an Eden product because they have developed it themselves, without an approach from another, as with Corteva, at least to the best of my knowledge. The insecticide will/should, be Eden's biggest opportunity in terms of sales revenue. Finally, last time I calculated, with the current shares in issue, £5 million profit was worth 28p a share on 30* earnings with nothing built in for the future. Alex Abrey recently said on film, that in management's opinion the shares are worth north of 20p today, thus exceeding the Cavendish 20p target. A £10 million profit on the same basis is 56p a share. I don't think we are too many steps away in execution or time to exceed both of these numbers. |
Posted at 01/7/2024 20:55 by supersonico NUMBER OF AIM SECURITIES IN ISSUEAs of 21 June 2024, the number of shares in issue was 533,352,523. As of 21 June 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,037,526 10.51% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 41,915,712 7.86% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,964,424 4.31% JM Finn Nominees Limited 19,955,562 3.74% Amati Global Investors 16,744,070 3.14% Name Number of shares % of the issued ordinary share capital A Abrey 1,774,192 0.33% L van der Broek 1,621,808 0.30% S Smith 1,192,577 0.22% R Cridland 745,552 0.14% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 3 January 2024, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 53,364,313 10.01% Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Interactive Investor 33,363,457 6.26% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,099,924 4.14% JM Finn Nominees Limited 20,147,562 3.78% Amati Global Investors 16,744,070 3.14% BGF Investment Management Limited 16,000,576 3.00% .................... As of 20 July 2023, the number of shares in issue was 381,108,607. SIGNIFICANT SHAREHOLDERS As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 45,307,219 11.89% Sipcam Oxon S.p.A. 37,614,830 9.87% Interactive Investor 31,957,945 8.39% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% BGF Investment Management Limited 20,233,000 5.31% JM Finn Nominees Limited 19,635,562 5.15% Atul Unadkat 18,811,765 4.94% Rathbone Nominees Limited 13,661,661 3.58% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% HSDL Stockbrokers 12,436,733 3.26% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% ................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 March 2023, the number of shares in issue was 380,858,607. SIGNIFICANT SHAREHOLDERS As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 51,733,000 13.58% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 31,737,596 8.33% Gresham House Asset Management Limited 27,845,445 7.31% Interactive Investor 25,172,555 6.61% Canaccord Genuity Group Inc 22,584,000 5.93% JM Finn Nominees Limited 19,839,762 5.21% Atul Unadkat 18,117,567 4.76% Rathbone Nominees Limited 15,621,872 4.10% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% SHARES NOT IN PUBLIC HANDS In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands. .................... Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN Selling yes..but it's a dribble which has been bought by Atul etal. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% 1 |
Posted at 27/6/2024 07:15 by supersonico BIOINSECTICIDE FIELD TRIALS.Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technologies for use in the global crop protection, animal health and consumer products industries, is pleased to provide an update on the development of its bioinsecticide product following the receipt of recent field trial reports. The trials, which were undertaken by several potential commercial partners for the product, as well as by Eden, represent a significant milestone in the process of bringing the Company's new bioinsecticide to market as Eden continues to develop and expand its product portfolio, in line with its business strategy. In the more than 30 laboratory trials and more than 140 field trials run in Europe and the United States, the developmental bioinsecticide product was tested against aphids, spider mites, whiteflies and other target pests at various stages of their development. Results showed strong efficacy against all life stages of these key pests and equivalent or superior performance when compared with registered biological reference products produced by some of the world's leading biochemical companies. Every year, up to 40% of crops are lost due to plant pests and diseases, whilst the United Nations estimates that 50% more food will be needed to feed the world's growing population by 2050. Insects remain one of the most significant challenges to farming efforts across the globe, causing both direct and indirect damage to crops through feeding and the transmission of disease, costing the global economy an estimated $70 billion a year, according to the UN's Food and Agriculture Organization. At the same time, conventional insecticide products face increased regulatory scrutiny due to their potential for harmful effects on the environment and wildlife, including bees and other beneficial insects. Demand is high for sustainable products, like Eden's bioinsecticide, that can provide farmers with sustainable and competitive alternatives, providing similar ease-of-use, efficacy, safety, cost and reliability, representing a significant global market opportunity for Eden. Sean Smith, Chief Executive Officer of Eden Research, commented: "These promising results further demonstrate Eden's ability to develop market-leading biological formulations at a time when conventional insecticide products are being phased out due to regulatory action. The trials, undertaken by Eden and independently by several potential commercial partners interested in gaining rights to the product, show extremely promising efficacy and consistency in combating these pests known to critically impact crop yields. This is an exciting step in our journey to bring this product to farmers who are looking for effective, sustainable solutions to control pests, whilst also making further progress against our product diversification and business growth objectives." |
Posted at 20/6/2024 15:30 by erinvale1 Eden share price falls significantly once again - currently -10%. This company has gaslighted its shareholders for decades. It is destined to fail, but Sean Smith obviously considers he is doing a good job. |
Posted at 18/6/2024 01:27 by neutralpov > Eden will likely see exponential growth at some stage and a share price to match.Yes, yes, share price 0p to/from which all rates will be exponential. You flukkedwits kill me, ROTFL!! |
Posted at 15/6/2024 11:39 by investingisatrickygame Building a company is not easy. Anyone who has tried will have sympathy with that.Being a minnow, short of cash, competing with global players, is not easy. Anyone who has tried will have sympathy with that. Developing a product(s) and technologies that global players can go global with AND WANT is a massive achievement. Eden will likely see exponential growth at some stage and a share price to match. It will have been years in the making and look like a share price spike, but in reality it should be a recognition point and value alignment for time invested and success achieved. We'll see. |
Posted at 11/6/2024 13:52 by supersonico Seems an appropriate time to repost 7722;supersonico 18 May '20 - 14:44 - 7722 of 17779 Edit 0 1 0 So much time on my Hands Updated fully referenced..SustainE Collaborators News aka..when the Farmboys get twitchy you know your getting close..News Eden.. Sumitomo (Valent Bioscience /Sipcam) /Corteva /Bayer etal Collaboration. The next-generation encapsulation system to help us solve a broader set of challenges for our partners.' 27 März 2017 Dow, BASF, Eastman stir up new formulas for safer chemicals Consumer marketplace seems to be the most powerful force inspiring chemical and materials manufacturers to create safer chemicals. 2017 Eden Reset UMMS commercial terms. Sean Smith, Chief Executive of Eden, said: "We are pleased to announce the re-setting of some of the key commercial terms of our licence agreement with UMMS. We believe that the new terms reflect both the long term potential of our next-generation encapsulation technology whilst also reflecting the current stage of technology development. We look forward to the ongoing collaboration with UMMS which is, in part, focussed on the further development of this technology with the objective of creating a next-generation encapsulation system to help us solve a broader set of challenges for our partners." Later that year Ex Bayer linkman Lykele joins EDEN A Patent from UMMS, Authored by Gary Ostroff and Ernesto Soto Senior Research Scientist at UMass Medical School/ Monsanto YEAST CELL WALL PARTICLE ENCAPSULATION OF BIODEGRADABLE PRO-PAYLOADS This is STATEMENT OF FEDERALLY SPONSORED RESEARCH This invention was made with government support under Grant Nos. NIFA 2015-11323 awarded by the United States Department of Agriculture (USDA) National Institutes of Food and Agriculture (NIFA). The government has certain rights in this invention. This patent discusses improvements in the encapsulation process and in particular reference to Agricultural and Industrial Compositions and Methods ; 'The composition of the present disclosure may alternatively be applied via irrigation. This is suitable for treating nematodes or other soil borne pathogens or parasites. In certain embodiments, the present disclosure provides for compositions in the form of granules and methods of controlling pests using the same. Granules allow for the use of less selective herbicides, pesticides, and combinations thereof, and thus offer a means to control pests that are not otherwise easily controlled. Granules are a convenient application form for producers with small allotments such as paddy rice farmers, or for growers of turf where spays are complicated by the needs of near neighbors sensitive to drift or odor or for broad acre farmers who wish to apply fertilizers and herbicides together and who do not have convenient access to water. The granules may be used in flooded paddies, recently irrigated turf, or in areas where it is inconvenient or impossible to remove irrigation water. The granules allow small holders the means to apply crop protection chemicals without expensive equipment, and without risk of exposing airways or eyes to aerosols or spray materials. Granules can be easily measured and distributed by hand. Using granules that are designed for uniform dispersal is advantageous because this compensates for uneven application'. Now Monsanto Bayer have a huge issue with Dicamba Drift and Globally their is a significant issue with Rice Blast a key issue for many AG companies including Corteva and Bayer. I repeat the earlier UMMS paragraph; 'We look forward to the ongoing collaboration with UMMS which is, in part, focussed on the further development of this technology with the objective of creating a next-generation encapsulation system to help us solve a broader set of challenges for our partners' A Corteva note says; 'Corteva Agriscience has committed to improving the livelihoods of at least 3 million farmers and their rural communities by the end of 2020. Within this corporate target, the company specifies its Rice Farm Schools Program in India, a collaboration with the Uttar Pradesh Department of Agriculture that will provide half a million smallholder farmers with practical expertise and agronomic training. The project aims to have a multiplier effect, whereby farmers train other farmers using an eight-step program'. Notable Findings, 'Corteva Agriscience estimates that around 80% of its clientele in South and Southeast Asia are smallholder farmers'. The company engages approximately 1,000 third parties to organize seed production activities in India, through which the company uses long term contracts to solidify its relationships with 58,000 seed producers, of which 80% are estimated to be smallholder farmers. Also perhaps relevant and emphasises Rice Blast as a significant Global issue ; Dow DuPont merger conditions open door to new R&D player. 'The buyer would join BASF, Bayer, Syngenta and the merged entity as a global pesticide R&D organisation involved in the discovery of new active ingredients through to the release of formulated products through national distribution channels. The Commission found the merger would have significantly reduced competition for some selective herbicides for cereals, oilseed rape, sunflower, rice and pasture in a number of EU member states, as well as insecticides used in horticulture and fungicides used on rice blast. The merger conditions also required some DuPont insecticides used in horticulture and fungicides used on rice blast to be divested, and Dow would divest significant petrochemical investments in this sector where both companies currently operate'. .. This Paper.. Rice Blast: A Disease with Implications for Global Food Security describes 'Rice blast is a serious fungal disease of rice (Oryza sativa L.) that is threatening global food security' Further suggestions of corporate connections to Corteva come from this UMMS and Eden research funded summarising article presented at TechConnect World 2019 Program - Wednesday June 19 with Session chair: YuanQiao Rao of The Dow Chemical Company under the banner ..Materials for Personal/Home Care & Cosmetics Here they report 'an improved approach to develop controlled release YCWP Terpenes by encapsulating Biodegradable pro-terpene compounds' Interestingly Session chair: YuanQiao Rao has links to Eastman as well as Dow. Did someone say 100 times ...CAP/TT formulation parallel delay?? Ok so I hear you say ..so what Supersonico your just doing your all wild guesses all the wild time and making associations which may or may not have any relevance to Eden..to which I say Look at some of Eden's scientific advisors which include; Dr Paul Williams Belfast School of Biological Sciences who knows a fair bit about Rice cultivation and who's RESEARCH FOCUS is; Over the past 17 years Paul's focus has been to identify and attempt to correct the hidden inequality existing in global diets, a quest that’s taken him to the tannery slums of Dhaka, through to inaccessible mountain-dwelling communities in China poisoned by selenium – an element more commonly viewed in the “Westâ& Also Advising Eden we have.. Chang Hyun Khang an Associate Professor of Plant Biology who's Research Interests include; Fungi are major pathogens of plants. We are interested in understanding how fungi manipulate plant cells to cause disease and how plant cells respond to the invading fungi. To answer these questions, we study rice blast disease caused by the fungal pathogen Magnaporthe oryzae. Rice blast remains one of the world's most devastating diseases, destroying enough rice to feed more than 60 million people each year. In addition to its economic significance, rice blast is a model system for the study of plant-fungal interactions. We hope that our research will have translational value for controlling rice blast and other fungal diseases. Grants: 2014 – 2017 U.S. Department of Agriculture, Agriculture and Food Research Initiative Program. Trafficking mechanism of blast effector molecules during rice blast disease. PI: Khang, C.H. You could consider relevant also add to the mix .. Eden's recent Appointment of Director of Regulatory Affairs Dr. Michael Carroll who has considerable experience at Dow AgroSciences and Monsanto Agricultural Group and could also be providing DOW/Corteva with a linkman into Eden in a similar senior link role that I imagine Lylele has. Eden tell us 'At Monsanto and Dow AgroSciences, Mike's responsibilities included the global launch of herbicides and fungicides, experience which will be highly relevant as Eden executes on plans to expand its product offering'. Bear this in mind with the details of recent £10m fundraise and the Microplastic issue facing Corteva and every seed company on the planet. and 2017 Sumitomo/ dupont seed collaboration news; DuPont and Sumitomo Chemical Company Announce Global Seed-Applied Technology Agreement [...] "We are excited about this collaboration with Sumitomo Chemical. The Sumitomo Chemical portfolio and pipeline will complement the investments DuPont has made in discovery, development and commercialization of seed-applied products. Partnering with Sumitomo Chemical early in the development process enables us to create higher performing seed-applied products for our customers," said Mick Messman, director, DuPont Seed Applied Technologies. Collaborations between DuPont and Sumitomo Chemical's regional affiliate, Valent U.S.A. LLC., will focus on the North American region with potential expansion opportunities to multiple crop markets globally. [...] The RNS ' Sipcam exercises Option for new distribution agreements in additional territories' links Sipcam and Valent Bioscience to EDEN and relationships are discussed further in previous post 5395. Of note and pertinent here is the following paragraph; 'In addition to the new distribution agreements to be signed by the two parties, collaboration work continues with Sipcam in respect of Eden's natural microencapsulation technology, Sustaineâ„¢, which is being assessed for synergy with a number of active ingredients used in crop protection. Using the Sustaine technology potentially brings a number of advantages to existing conventional and natural active ingredients such as enhanced efficacy, formulation stability, patent protection, time-release and resistance management'. Of course this could all add up to a big bowl of wild speculation but I would consider it carefully before you follow the example of those shape shifting Gamekeepers turned poachers who are dismissive of the efforts of Team at Eden research and are imo currently over playing their hands. AWGATWT. |
Posted at 19/5/2024 10:18 by alchemy I like this Enterprise for various reasons . The main reason is like many here I want the share price up for personal gain that's for sure. So I like it because on balance I'm pretty sure that will ensue. But also look what it is and what it's not. And it has features, good ones. that lift it above othet companies on AIM. ( Every company on AIM needs extra sparkle at the moment ).So, EDEN.It's not damaging.It's not about mining for barbaric relics It is helpful to a big group called farmers .It's not either or when it comes to the adjective Organic.It encapsulates - hee - conventional and current and the emerging.It's not bound up in the fossil fuel issues.It's passed testsIt's not military Yes it's got a gating factor called regulation but it's passed crucial scrutiny in that regardIt's not about warOr Religion I can't think of any negatives . Ah it does need time for others to get the inevitability of all this . Back to the Share PriceWe have sufficient cash to be funded until profit. I still don't know about margins but someone here way back thought 40 per cent wasn't a push . The main flows will be joined by an other main flow - insecticide - then another and by smaller tributaries . Sustaine Natural Eden what's not to like? |
Posted at 22/4/2024 12:10 by investingisatrickygame The trend in the Eden share price has not been any of our friends.Can we see the bend? What is it and what does 'zoom that goes boom' look like for shareholders? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
